Updated 10:20 GMT, 16 Nov 2026 SPX 7,561.67 -0.40% NDX 27,943.74 -1.22% VIX 20.14 +4.35% GOLD 3,866.50 -0.51% CL 88.41 -0.17% BTC 64,365.95 -1.44%
NAS100 27,944 −1.22% S&P 7,562 −0.40% GOLD $3,867 −0.51% BTC $64,366 −1.44% VIX 20.14 +4.35% latest tape · as of 10:20 UTC
The Screen · Consumer Defensive · Beverages - Brewers

The Boston Beer Company, Inc. logoThe Boston Beer Company, Inc.

SAM · the NYSE · USD · Market cap $2.2B · 2,736 employees

The Boston Beer Company, Inc.

FAIL · Does not pass the screen
221.82 USD

Price as of 13 Nov 2026Daily close, not a live quote

Screened 2026-11-13 · the tape above runs as of 10:20 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price221.82 USD at the 13 Nov 2026 close
  • Our value readOvervalued vs our fair value, as of 13 Nov 2026
  • Our regime readMarkup, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • OptionsOpen interest leans heavily to calls (put/call 0.34)
  • Last reviewed13 Nov 2026 (3 days ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: $137.70 to $166.72, base estimate $144.97 (screen dated 2026-11-13).

Current read
Markup ?
Overvalued · screened 2026-11-13
  • Trend Markup
  • Insiders no filings inside 60 days, left as found
  • Positioning no disclosures inside 60 days, left as found
  • Options put/call open interest 0.34, read 2026-11-15
  • Ethical does not pass the values gate
Price221.82 USD
Fair value144.97
Ethical score30.0/100
Value readOvervaluedas of 13 Nov 2026
Our investment reviews on this name
2026-11-05Read Markup228.32-2.8% to today Accumulation gives way to Markup after a 37% rise in 4 weeks
2026-10-11Read Accumulation166.25+33.4% to today ✓Markdown gives way to Accumulation
2026-10-02Read Markdown166.25+33.4% to today Distribution gives way to Markdown after a 9% slide in 13 weeks
2026-07-02Read Distribution181.89+22.0% to today First review on file: Distribution

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its markup label.

The Boston Beer Company, Inc. holds its Markup at $221.82. Consolidating, no directional conviction, held for 100 days.

As held on the ledger · 2026-11-13
PhaseMarkup
Quantitative stateConsolidating, no directional conviction, held for 100 days
Price at the screen$221.82
ValuationN/A trailing · 21.00 forward price to earnings
Values screenFAIL · score 30.0
Beta0.80
The Workings

Five Screens, Shown in Full

Does not pass. Prohibited business activity: Brewers

TestFigureLimitWhat it meansStatus
Business activity Excluded Core business clean Prohibited business activity: Brewers Fail
Debt load Excluded Below 33% Interest-bearing debt is of its assets, above the one-third ceiling the screen allows. Fail
Interest-bearing cash Excluded Below 33% Interest-bearing cash and securities are of assets, above the one-third limit. Fail
Receivables Excluded Below 49% Money owed to the company is of assets, above the 49% limit. Fail
Revenue purity Excluded Below 5% of revenue comes from non-compliant sources, over the 5% line. Fail

Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.

The Ethical Read

Why It Falls Short, in Plain English

The Boston Beer Company, does not clear the screen at the business-activity stage. It operates in alcohol, so the financial ratios are not the deciding factor here.

Read as at 2026-11-15. It updates when the underlying figures move, and past reads are kept below.

Follow this verdict

Get an email when SAM's ethical verdict changes

Today SAM does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Our analysis reads Overvalued vs our fair value, as of 13 Nov 2026: it trades above our $144.97 fair value estimate.

How a fair value is estimated: discounted cash flow (DCF).

137.70Conservative144.97Base case166.72Growth case 221.82Price

Fair value range in USD, drawn from the 2026-11-13 screen. The gold marker is the market price at the same screen. The price runs 53.0% above the base estimate.

The Street's Range
153.00Street low 197.00Street average 295.00Street high 221.82Price

Third-party analyst targets: 13 covering, consensus Hold. The average target sits −11% from the screen price.

Reading the gap · Both our model and the Street see limited upside at this price.

Price History & Projections

Where our models see it going: fair-value estimate $144.97, with a range of $137.70 to $166.72, dated to the 2026-11-13 screen.

Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.

The Business, in Plain Words

Boston Beer fails the ethical screen outright

A cold Samuel Adams might taste fine after work, yet the company behind it runs straight into our ethical line. Brewers sit on the prohibited list, so we pass without hesitation. The numbers offer no reason to argue the point either, with revenue shrinking 4 percent, margins in negative territory and return on equity at minus 8 percent.

Our fair value sits at 158 dollars against a market price of 179, leaving no margin of safety and a forward multiple that offers little comfort for a business this weak. Thirteen analysts call it a hold with a higher target, but that view ignores the ethical screen that exists precisely for cases like this one.

The real risk lies in treating any alcohol producer as just another consumer name when the screen has already drawn the boundary. Analysis, not advice.

The fundamentals · plain-English read
Forward P/E21.0xa premium valuation
EPS, trailing-6.80
EPS, forward10.33
Revenue growth-3.2%revenue is shrinking
Profit margin-3.8%currently unprofitable
Return on equity-8.9%not currently earning a positive return on equity
FCF yield15.95%
Debt to equity4.02heavy leverage: higher risk if revenue softens
Current ratio1.13adequate liquidity, worth monitoring
Beta0.80steadier than the market
Short interest, float0.26%
52-week range158.68 - 264.46
Market cap$2.2B
Employees2,736

Another profit measure, before interest, tax and non-cash costs: EBITDA.

The risks · The things to watch: it carries a real debt load, which raises the stakes if revenue slips.

Plain-English interpretation of our own screen data. Analysis, not advice.

Where & How to Trade

SAM trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-12 Markup $219.16 -4.0% Entry 18

The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 4.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (13 analysts) rates it none, with a mean price target of $230.

2026-11-05 Markup · changed $228.32 +14.0% Entry 17

The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 14.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (13 analysts) rates it none, with a mean price target of $230. Since the last review it dropped out of the Titan Ethical 500.

2026-10-29 Accumulation $200.30 +12.4% Entry 16

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 12.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (13 analysts) rates it none, with a mean price target of $230.

2026-10-22 Accumulation $178.14 +0.0% Entry 15

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (13 analysts) rates it none, with a mean price target of $230. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-21 Accumulation $178.14 +0.0% Entry 14

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (13 analysts) rates it none, with a mean price target of $230. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-20 Accumulation $178.14 +0.0% Entry 13

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (13 analysts) rates it none, with a mean price target of $230. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-19 Accumulation $178.14 +0.0% Entry 12

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (13 analysts) rates it none, with a mean price target of $230. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-18 Accumulation $178.14 +0.0% Entry 11

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 17% above its long-term trend line with momentum reading bearish. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (13 analysts) rates it none, with a mean price target of $230. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-17 Accumulation $178.14 +0.0% Entry 10

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 17% above its long-term trend line with momentum reading bearish. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (13 analysts) rates it none, with a mean price target of $230. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-16 Accumulation $178.14 +0.0% Entry 9

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is holding around 17% above its long-term trend line with momentum reading bearish. Over the past year the shares are down 20%. Our forward projection puts the odds of a 10% gain over the next month near 15%. The street (13 analysts) rates it none, with a mean price target of $230. It reported earnings in this window, a natural checkpoint for the thesis.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

Latest News · What the Market Is Reading on SAM

Headlines from third-party outlets, linked for reference: not our reporting, not advice.

Related Securities · Others in SAM's Space

Screened names in the same industry · explore each on its own page.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $188.54 -6.2% · $938 -6.2%
2 months $257.21 -31.3% · $688 -31.3%
3 months $229.20 -22.8% · $772 -22.8%
6 months $199.47 -11.4% · $887 -11.4%
1 year $220.03 -19.6% · $804 -19.6%
2 years $291.80 -39.4% · $606 -39.4%
3 years $328.49 -46.2% · $538 -46.2%
5 years $1,028.96 -82.8% · $172 -82.8%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever SAM does next, these words stay.

The Boston Beer Company, Inc. · SAM · Markup · $221.82
Recorded 2026-11-13 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.